Hoffmann-la Roche Inc.

Madrigal Pharmaceuticals, Inc.

F. Hoffmann-la Roche Ag

Nicholas Marcopulos

Adrian Wai-Hing Cheung

Yimin Qian

Fariborz Firooznia

David Robert Bolin

Kevin Richard Guertin

Jenny Tan

Lida Qi

Jefferson Wright Tilley

Matthew Michael Hamilton

Sung-Sau So

Ramakanth Sarabu

Nancy-Ellen Haynes

Eric Mertz

Kshitij Chhabilbhai Thakkar

Lee Apostle McDermott

John A Brinkman

Stuart Hayden

Joseph Anthony Bilotta

Jagdish Kumar Racha

Christine M Lukacs-Lesburg

The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula I: wherein the variables are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.

Aminomethyl quinolone compounds

Provided herein are compounds of the formula (I): were RI is phenyl, R2 is hydrogen, halogen or lower alkyl, X is carbon on nitrogen, and R3 is isoquinoline, -amino, or a -4- to 6-membered heterocycloalkyl ring and pharmaceutically acceptable salts thereof, which are active as DGAT inhibitors and therefore find uses in treatment of diseases associated with abnormal metabolism of trigliceride. such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

Diacylglycerol acyltransferase inhibitors

Provided herein are amides containing at least a four ring structure, which are inhibitors of diacylglycerol acyltransferase and are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

Inhibitors of diacylglycerol acyltransferase

There are presented compounds of the formula  or a pharmaceutically acceptable salt thereof, which are active adenosine A2B receptor antagonists and useful in the treatment of diabetes, diabetic retinopathy, asthma and diarrhea.

Substituted thiazolo[5,4-d]pyrimidine urea derivatives

Growing community of inventors

North Caldwell, NJ, United States of America

Nicholas Marcopulos